American Society of Hirudotherapy

Keloid and Hypertrophic Scarring

Investigational use for keloid and hypertrophic scars; evidence is limited to one small uncontrolled series and two conflicting single-patient reports.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for keloid or hypertrophic scars. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for scar modification is investigational.
What evidence exists?
Tier C (investigational). Only very limited clinical reports exist: one small uncontrolled Russian series (18 patients with post-gunshot scars) and two single-patient case reports with opposite outcomes; there are no controlled trials. Evidence-based first-line therapy for keloid and hypertrophic scars is intralesional triamcinolone (sometimes combined with 5-fluorouracil), silicone gel sheeting or silicone gel, pressure therapy, and for keloids resistant to medical therapy, surgical excision combined with adjuvant radiation or intralesional steroid. Cryotherapy and laser therapies are additional options for hypertrophic scars.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the scar area for 5 to 10 days
  • Worsening of the keloid (paradoxical growth — keloids have unpredictable response to trauma)
  • New keloid formation at the bite sites themselves in keloid-prone individuals
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Post-inflammatory hyperpigmentation, especially in darker Fitzpatrick skin types
  • Delay or replacement of evidence-based intralesional therapy
  • Permanent scarring or pigment change at bite sites
Who should not consider this
  • Patients within 6 weeks of scar revision surgery
  • Patients with active scar infection or drainage
  • Patients with strong keloid diathesis (multiple keloids, family history of severe keloids) — bite scars may keloidize
  • Patients with darker Fitzpatrick skin types at high risk of post-inflammatory hyperpigmentation
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not tried evidence-based intralesional steroid or silicone therapy
  • Patients with active wound or ulceration of the scar
  • Patients with recent intralesional corticosteroid injection within 4 weeks
  • Patients undergoing active radiation therapy field treatment
What to ask your clinician
  • Has my scar been classified as keloid (extends beyond original wound) or hypertrophic (within wound boundary)?
  • How old is the scar? Mature keloids (over 2 years) respond less to any therapy.
  • Have I tried intralesional triamcinolone (with or without 5-FU)? It is first-line and well-evidenced.
  • Have I tried silicone gel sheeting or pressure garments for at least 3 months?
  • If keloid is severe, am I a candidate for excision with adjuvant radiation or intralesional steroid?
  • What is my keloid recurrence risk after any intervention?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the risk that bite sites themselves will form new keloids?
  • Are leeches from an FDA-registered supplier and used only once?
When to seek urgent care
  • Rapidly growing scar with pain, color change, or ulceration (rule out malignancy)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F or chills
  • Sudden severe pain or itching unresponsive to usual measures
  • Hives, throat tightness, or breathing difficulty

What this does NOT mean

  • This is not FDA-cleared for keloid or hypertrophic scars.
  • A small uncontrolled series and single-patient reports do NOT establish efficacy versus intralesional triamcinolone or silicone therapy.
  • Mechanism rationale (ECM remodeling, antifibrotic peptides) does NOT establish clinical equivalence to proven therapies.
  • Keloid-prone patients may develop new keloids at bite sites — this risk is real and unpredictable.
  • Leech therapy is not a substitute for intralesional steroid, silicone, pressure therapy, surgical excision with adjuvant therapy, or laser when indicated.
  • Leech therapy does NOT cure keloids — recurrence is common without combination therapy.

Clinical Profile

Category
Dermatological
ICD-10
L91.0, L98.0
Safety tier
Low

Evidence Summary

No controlled clinical trial of leech therapy for keloid or hypertrophic scarring was identified, and no study reported scar height or Vancouver Scar Scale scores. The clinical reports found are very limited: an uncontrolled Russian conference series of 18 patients after surgical treatment of gunshot wounds of the lower limb, in whom leech therapy formed part of a rehabilitation regimen and scar softening and increased elasticity were noted in 15 (Sulim & Volokitin 2003, as summarized in the Baskova and Isakhanyan 2004 monograph); one patient with a post-traumatic keloid above the knee whose keloid resolved (Iqbal et al. 2016); and one patient in whom a keloid-like scar developed despite leech applications after cyst excision (Sonani et al. 2023). Any proposed mechanism (salivary enzyme or peptide effects on extracellular matrix remodeling, or reduction of local microvascular congestion) is speculative and unproven in this condition. Established first-line and adjunctive measures (intralesional triamcinolone, silicone gel sheeting, pressure therapy, and, in selected cases, surgical excision with adjuvant treatment) remain the standard and should be directed by a dermatologist. ASH position: any use of leech therapy for keloid or hypertrophic scars is investigational and supported only by very limited clinical reports.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • Baskova and Isakhanyan mention keloid scars only once — in the list of indications for hirudotherapy, among the surgical ones: it lists prevention of keloid scar formation in patients with gunshot wounds of the lower limbs; the book has no separate discussion of keloids, no treatment method for them and no results[B1].
  • Closest to the topic are the observations of Sulim and Volokitin (2003), which the authors retell: 18 patients with gunshot wounds of the lower limbs received hirudotherapy in the recovery period after surgery as part of a treatment complex; according to this account, the pain disappeared in all of them, softening of the scar and increased elasticity were noted in 15, and in 3 there was no effect[B1].
  • In the retelling of these observations itself, the word keloid is not used, and it does not say whom these patients were compared with, how the scar was assessed or how long they were followed[B1].
  • Hypertrophic scars under that name, and keloids that do not respond to corticosteroid injections, are not discussed in either book; keloids appear in Michalsen et al. only in cautions, which are described below[B1][B3].
  • Flecken and Michalsen (chapter on contraindications) write that leech bites can result in keloid formation in people who tend to develop keloids, and that the patient should therefore be asked about any history of scars and keloids[B3].
  • Michalsen (chapter on safety) writes that if the bite site is left undisturbed, the mark usually quickly shrinks to a barely visible spot and disappears completely within one to three weeks; but if healing is disturbed (scratching, secondary infection of the wound), the marks may remain visible for much longer[B3].
  • Baskova and Isakhanyan consider hirudotherapy relatively contraindicated when leeches could potentially lead to cosmetic defects; among the contraindications they also name hemophilia, anemia and the use of anticoagulants[B1].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active scar infection
  • Within 6 weeks of scar revision surgery
  • Active wound or ulceration in the scar
  • Recent intralesional corticosteroid injection (<4 weeks)
  • Active radiation therapy field

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.